C3b alone does not mediate cytotoxicity or phagocytosis but greatly enhances IgG-induced phagocytosis or cytotoxicity through adherence to the complement receptors (for C3b only) on mononuclear cells.

Autoimmune hemolytic anemia (AIHA) is a rare type of anemia that is diagnosed in only about 1-3 people per 100,000. Anemia is when your bone marrow doesn't make enough red blood cells.

Johnson & Johnson (NYSE: JNJ) announced today findings from several online abstracts and posters on patients living with warm autoimmune hemolytic anemia (wAIHA), a rare, life-threatening ...

Microangiopathic hemolytic anemia vs. disseminated intravascular coagulation (DIC) Disseminated intravascular coagulation (DIC) is also a condition that affects the blood.

Hemolytic anemia is a type of anemia where RBCs are destroyed faster than they can be produced. Sometimes, this is due to an underlying condition, but other times, there’s no known cause.

Autoimmune hemolytic anemia (AIHA) is a rare disorder that causes your immune system to attack healthy red blood cells (RBCs) by accident. This can lead to anemia, causing symptoms like fatigue ...

Hemolytic anemia is a condition that occurs when the body destroys red blood cells faster than it replaces them, causing symptoms such as weakness, dizziness, or jaundice. Learn more.

A complete blood count (CBC) might suggest hemolytic anemia if your RBC, hemoglobin, and reticulocyte counts are low. But further testing may be required. Anemia occurs when you don’t have ...

Anemia is a condition where your body has a reduced number of red blood cells. Learn more about the types, symptoms, causes, diagnosis, and treatment.

“The Red Cell Revolution advisory council is designed to build connections among PK deficiency, thalassemia and sickle cell disease advocates and thought leaders, and to generate insights to raise ...

Bites from brown recluse spiders can cause an autoimmune form of hemolytic anemia, in which red blood cells are destroyed by the immune system. When you purchase through links on our site, we may ...

European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is the first-and-only approved therapeutic option approved ...